Search

Your search keyword '"Le Coutre, Philipp"' showing total 989 results
Start Over Author "Le Coutre, Philipp"
989 results on '"Le Coutre, Philipp"'

1. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)

Author

Isfort, Susanne, von Bubnoff, Nikolas, Al-Ali, Haifa Kathrin, Becker, Heiko, Götze, Thorsten, le Coutre, Philipp, Griesshammer, Martin, Moskwa, Claudia, Wohn, Luisa, Riedel, Johanna, Palandri, Francesca, Manz, Kirsi, Hochhaus, Andreas, Döhner, Konstanze, and Heidel, Florian H.

Published
2024
Full Text
View/download PDF

2. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results

Author

Cortes, Jorge E., Sasaki, Koji, Kim, Dong-Wook, Hughes, Timothy P., Etienne, Gabriel, Mauro, Michael J., Hochhaus, Andreas, Lang, Fabian, Heinrich, Michael C., Breccia, Massimo, Deininger, Michael, Goh, Yeow Tee, Janssen, Jeroen J.W.M., Talpaz, Moshe, de Soria, Valle Gomez Garcia, le Coutre, Philipp, DeAngelo, Daniel J., Damon, Andrea, Cacciatore, Silvia, Polydoros, Fotis, Agrawal, Nithya, and Rea, Delphine

Published
2024
Full Text
View/download PDF

3. Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy

Author

Gross, Sophia, Ihlow, Jana, Busack, Leonie, Adamiak, Kacper, Schrezenmeier, Jens, Jesse, Julia, Schwarz, Michaela, Flörcken, Anne, Vuong, Lam Giang, Rieger, Kathrin, Krönke, Jan, le Coutre, Philipp, Boldt, Vivien, von Brünneck, Ann-Christin, Horst, David, Burmeister, Thomas, Blau, Igor-Wolfgang, Keller, Ulrich, Bullinger, Lars, and Westermann, Jörg

Published
2024
Full Text
View/download PDF

4. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

Author

Mauro, Michael J., Hughes, Timothy P., Kim, Dong-Wook, Rea, Delphine, Cortes, Jorge E., Hochhaus, Andreas, Sasaki, Koji, Breccia, Massimo, Talpaz, Moshe, Ottmann, Oliver, Minami, Hironobu, Goh, Yeow Tee, DeAngelo, Daniel J., Heinrich, Michael C., Gómez-García de Soria, Valle, le Coutre, Philipp, Mahon, Francois-Xavier, Janssen, Jeroen J. W. M., Deininger, Michael, Shanmuganathan, Naranie, Geyer, Mark B., Cacciatore, Silvia, Polydoros, Fotis, Agrawal, Nithya, Hoch, Matthias, and Lang, Fabian

Published
2023
Full Text
View/download PDF

5. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

Author

Hochhaus, Andreas, Réa, Delphine, Boquimpani, Carla, Minami, Yosuke, Cortes, Jorge E., Hughes, Timothy P., Apperley, Jane F., Lomaia, Elza, Voloshin, Sergey, Turkina, Anna, Kim, Dong-Wook, Abdo, Andre, Fogliatto, Laura Maria, le Coutre, Philipp, Sasaki, Koji, Kim, Dennis Dong Hwan, Saussele, Susanne, Annunziata, Mario, Chaudhri, Naeem, Chee, Lynette, García-Gutiérrez, Valentin, Kapoor, Shruti, Allepuz, Alex, Quenet, Sara, Bédoucha, Véronique, and Mauro, Michael J.

Published
2023
Full Text
View/download PDF

7. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

Author

Brümmendorf, Tim H., Cortes, Jorge E., Milojkovic, Dragana, Gambacorti-Passerini, Carlo, Clark, Richard E., le Coutre, Philipp, Garcia-Gutierrez, Valentin, Chuah, Charles, Kota, Vamsi, Lipton, Jeffrey H., Rousselot, Philippe, Mauro, Michael J., Hochhaus, Andreas, Hurtado Monroy, Rafael, Leip, Eric, Purcell, Simon, Yver, Anne, Viqueira, Andrea, and Deininger, Michael W.

Published
2022
Full Text
View/download PDF

8. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

Author

Kreitman, Robert, Dearden, Claire, Zinzani, Pier, Delgado, Julio, Karlin, Lionel, Robak, Tadeusz, Gladstone, Douglas, le Coutre, Philipp, Dietrich, Sascha, Gotic, Mirjana, Larratt, Loree, Offner, Fritz, Schiller, Gary, Swords, Ronan, Bacon, Larry, Bocchia, Monica, Bouabdallah, Krimo, Breems, Dimitri, Cortelezzi, Agostino, Dinner, Shira, Doubek, Michael, Gjertsen, Bjorn, Gobbi, Marco, Hellmann, Andrzej, Lepretre, Stephane, Maloisel, Frederic, Ravandi, Farhad, Rousselot, Philippe, Rummel, Mathias, Siddiqi, Tanya, Tadmor, Tamar, Troussard, Xavier, Yi, Cecilia, Saglio, Giuseppe, Roboz, Gail, Balic, Kemal, Standifer, Nathan, He, Peng, Marshall, Shannon, Wilson, Wyndham, Pastan, Ira, Yao, Nai-Shun, and Giles, Francis

Subjects
Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Bacterial Toxins, Drug Resistance, Neoplasm, Exotoxins, Female, Follow-Up Studies, Humans, Leukemia, Hairy Cell, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Remission Induction, Salvage Therapy, Survival Rate
Abstract

This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), a rare B cell malignancy with high CD22 expression. The study enrolled patients with relapsed/refractory HCL who had ≥2 prior systemic therapies, including ≥1 purine nucleoside analog. Patients received moxetumomab pasudotox 40 µg/kg intravenously on days 1, 3, and 5 every 28 days for ≤6 cycles. Blinded independent central review determined disease response and minimal residual disease (MRD) status. Among 80 patients (79% males; median age, 60.0 years), durable complete response (CR) rate was 30%, CR rate was 41%, and objective response rate (CR and partial response) was 75%; 64 patients (80%) achieved hematologic remission. Among complete responders, 27 (85%) achieved MRD negativity by immunohistochemistry. The most frequent adverse events (AEs) were peripheral edema (39%), nausea (35%), fatigue (34%), and headache (33%). Treatment-related serious AEs of hemolytic uremic syndrome (7.5%) and capillary leak syndrome (5%) were reversible and generally manageable with supportive care and treatment discontinuation (6 patients; 7.5%). Moxetumomab pasudotox treatment achieved a high rate of independently assessed durable response and MRD eradication in heavily pretreated patients with HCL, with acceptable tolerability.

Published
2018

9. Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios

Author

Saglio, Giuseppe, le Coutre, Philipp, Cortes, Jorge, Mayer, Jiří, Rowlings, Philip, Mahon, François-Xavier, Kroog, Glenn, Gooden, Kyna, Subar, Milayna, and Shah, Neil P

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Cardiovascular, Atherosclerosis, Cancer, Hematology, Clinical Trials and Supportive Activities, Aging, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Cardiovascular Diseases, Clinical Trials as Topic, Dasatinib, Female, Humans, Incidence, Ischemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Male, Middle Aged, Outcome Assessment, Health Care, Prostatic Neoplasms, Protein Kinase Inhibitors, Chronic myeloid leukemia, Ischemic, Tyrosine kinase inhibitors, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

With high survival rates for chronic myeloid leukemia (CML) patients treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs), emerging consequences, such as arterial ischemic events, require consideration when evaluating treatment options. Cardiovascular ischemic event incidence in clinical trials was evaluated in 2712 dasatinib-treated patients with Philadelphia chromosome-positive (Ph+) leukemias from 11 first- and second-line trials (pooled), newly diagnosed CML patients treated with dasatinib or imatinib (DASISION), and prostate cancer patients treated with dasatinib or placebo plus docetaxel/prednisone (READY). Overall, 2-4% of dasatinib-treated patients had cardiovascular ischemic events. Most dasatinib-treated patients with an event had a history of and/or risk factor for atherosclerosis (pooled 77 with history/risk and event/96 with events; DASISION 8/10; READY 15/18). Most cardiovascular ischemic events occurred within 1 year of initiating dasatinib (pooled 69/96; DASISION 7/10; READY 16/18). Comparison of observed and expected event rates through standardized incidence ratios indicates that dasatinib does not increase risk for cardiovascular ischemic events compared with external reference populations.

Published
2017

10. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial

Author

Radich, Jerald P., Hochhaus, Andreas, Masszi, Tamás, Hellmann, Andrzej, Stentoft, Jesper, Casares, María Teresa Gómez, García-Gutiérrez, J. Valentín, Conneally, Eibhlin, le Coutre, Philipp D., Gattermann, Norbert, Martino, Bruno, Saussele, Susanne, Giles, Francis J., Ross, David M., Aimone, Paola, Li, Sai, Titorenko, Ksenia, and Saglio, Giuseppe

Published
2021
Full Text
View/download PDF

11. Physical exercise recommendations for patients with chronic myeloid leukemia based on individual preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97)

Author

Hollenbach, Lina, primary, Rogahn, Julia, additional, le Coutre, Philipp, additional, Schulze, Susann, additional, Muegge, Lars-Olof, additional, Geissler, Jan, additional, Gruen, Julia, additional, Junghanss, Christian, additional, and Felser, Sabine, additional

Published
2024
Full Text
View/download PDF

12. VEXAS and Myelodysplastic Syndrome: An Interdisciplinary Challenge

Author

Kreutzinger, Virginie, primary, Pankow, Anne, additional, Boyadzhieva, Zhivana, additional, Schneider, Udo, additional, Ziegeler, Katharina, additional, Stephan, Lars Uwe, additional, Kübke, Jan Carl, additional, Schröder, Sebastian, additional, Oberender, Christian, additional, le Coutre, Philipp, additional, Stintzing, Sebastian, additional, and Jelas, Ivan, additional

Published
2024
Full Text
View/download PDF

13. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Author

Kantarjian, Hagop M., Hughes, Timothy P., Larson, Richard A., Kim, Dong-Wook, Issaragrisil, Surapol, le Coutre, Philipp, Etienne, Gabriel, Boquimpani, Carla, Pasquini, Ricardo, Clark, Richard E., Dubruille, Viviane, Flinn, Ian W., Kyrcz-Krzemien, Slawomira, Medras, Ewa, Zanichelli, Maria, Bendit, Israel, Cacciatore, Silvia, Titorenko, Ksenia, Aimone, Paola, Saglio, Giuseppe, and Hochhaus, Andreas

Published
2021
Full Text
View/download PDF

14. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity

Author

Schiffer, Charles A, Cortes, Jorge E, Hochhaus, Andreas, Saglio, Giuseppe, le Coutre, Philipp, Porkka, Kimmo, Mustjoki, Satu, Mohamed, Hesham, and Shah, Neil P

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Cancer, Hematology, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Antineoplastic Agents, Clinical Trials, Phase III as Topic, Dasatinib, Disease-Free Survival, Female, Humans, Imatinib Mesylate, Incidence, Killer Cells, Natural, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Lymphocytosis, Male, Middle Aged, Pleural Effusion, Protein Kinase Inhibitors, Randomized Controlled Trials as Topic, Retrospective Studies, T-Lymphocytes, Cytotoxic, dasatinib, leukemia, chronic myeloid, killer cells, natural, lymphocytosis, T-lymphocytes, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Public health
Abstract

BackgroundThe proliferation of clonal cytotoxic T-cells or natural killer cells has been observed after dasatinib treatment in small studies of patients with chronic myeloid leukemia (CML).MethodsThe incidence of lymphocytosis and its association with response, survival, and side effects were assessed in patients from 3 large clinical trials. Overall, 1402 dasatinib-treated patients with newly diagnosed CML in chronic phase (CML-CP), CML-CP refractory/intolerant to imatinib, or with CML in accelerated or myeloid-blast phase were analyzed.ResultsLymphocytosis developed in 32% to 35% of patients and persisted for >12 months. This was not observed in the patients who received treatment with imatinib. Dasatinib-treated patients in all stages of CML who developed lymphocytosis were more likely to achieve a complete cytogenetic response, and patients who had CML-CP with lymphocytosis were more likely to achieve major and deep molecular responses. Progression-free and overall survival rates were significantly longer in patients with CML-CP who were refractory to or intolerant of imatinib and had lymphocytosis. Pleural effusions developed more commonly in patients with lymphocytosis.ConclusionsOverall, lymphocytosis occurred and persisted in many dasatinib-treated patients in all phases of CML. Its presence was associated with higher response rates, significantly longer response durations, and increased overall survival, suggesting an immunomodulatory effect. Prospective studies are warranted to characterize the functional activity of these cells and to assess whether an immunologic effect against CML is detectable. Cancer 2016;122:1398-1407. © 2016 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.

Published
2016

15. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.

Author

Holdhoff, Matthias, Kreuzer, Karl-Anton, Appelt, Christine, Scholz, Regina, Na, Il-Kang, Hildebrandt, Bert, Riess, Hanno, Jordan, Andreas, Schmidt, Christian A, Van Etten, Richard A, Dörken, Bernd, and le Coutre, Philipp

Subjects
Benzamides, Breast Neoplasms, Cell Line, Tumor, Cell Survival: radiation effects, Colonic Neoplasms, Dose-Response Relationship, Radiation, Female, Glioblastoma, Humans, Piperazines: pharmacology, Pyrimidines: pharmacology, Radiation-Sensitizing Agents: pharmacology, Receptors, Platelet-Derived Growth Factor: antagonists & inhibitors
Abstract

Imatinib mesylate is a small molecule inhibitor of the c-Abl, platelet-derived growth factor (PDGF) receptor and c-Kit tyrosine kinases that is approved for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) and gastrointestinal stromal tumors. Glioblastoma multiforme is a highly malignant primary brain tumor that is usually treated with surgery and/or radiotherapy. Previous studies implicate an autocrine loop caused by high expression of PDGF and its receptor, PDGFR, in the proliferation of some glioblastomas. Here, we demonstrate that pretreatment of a human glioblastoma cell line, RuSi RS1, with imatinib significantly enhanced the cytotoxic effect of ionizing radiation. This effect was not seen in human breast cancer (BT20) and colon cancer (WiDr) cell lines. Whereas c-Abl and c-Kit were expressed about equally in the three cell lines, RuSi RS1 cells showed significantly higher expression of PDGFR-beta protein in comparison to BT20 and WiDr. Imatinib treatment of RuSi RS1 cells decreased overall levels of cellular tyrosine phosphorylation and specifically inhibited phosphorylation of PDGFR-beta, while c-Abl was not prominently activated in these cells. These results suggest that imatinib may have clinical utility as a radiosensitizer in the treatment of human glioblastoma, possibly through disruption of an autocrine PDGF/PDGFR loop.

Published
2015

16. Nilotinib

Author

Gresse, Martin, Kim, Theo D., le Coutre, Philipp, Schlag, Peter-Michael, Series Editor, Senn, Hans-Jörg, Series Editor, and Martens, Uwe M., editor

Published
2018
Full Text
View/download PDF

17. Addendum to the German Consensus Recommendations on Ponatinib in the Treatment of Chronic Myeloid Leukemia.

Author

Saussele, Susanne, La Rosée, Paul, Kiani, Alexander, Haverkamp, Wilhelm, Jentsch-Ullrich, Kathleen, Stegelmann, Frank, Rieger, Christina, Waller, Cornelius F., Franke, Georg-Nikolaus, Junghanss, Christian, Kirchmair, Rudolf, Theurl, Markus, and le Coutre, Philipp

Subjects
CHRONIC myeloid leukemia, DECISION trees, CARDIOVASCULAR diseases
Abstract

Background: Based on the new data from the primary analysis of the OPTIC (Optimizing Ponatinib Treatment in CP-CML) trial on dose optimization of ponatinib in patients with chronic phase (CP)-CML, the German consensus paper on ponatinib published in 2020 (Saussele S et al., Acta Haematol. 2020) has been updated in this addendum. Summary: Focus is on the update of efficacy and safety of ponatinib, reflecting the new data set, as well as the update of the benefit-risk assessment and recommendations for ponatinib starting dose in CP-CML – provided that the decision to use ponatinib has already been made. Furthermore, based on OPTIC and additional empirical data, the expert panel collaborated to develop a decision tree for ponatinib dosing, specifically for intolerant and resistant patients. The recommendations on cardiovascular management have also been updated based on the most recent 2021 guidelines of the European Society of Cardiology (ESC) on cardiovascular disease prevention in clinical practice. Key Messages: The OPTIC data confirm the high efficacy of ponatinib in patients with CP-CML and provide the basis for individualized dose adjustment during the course of treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Addendum to the German Consensus Recommendations on Ponatinib in the Treatment of Chronic Myeloid Leukemia

Author

Saussele, Susanne, primary, La Rosée, Paul, additional, Kiani, Alexander, additional, Haverkamp, Wilhelm, additional, Jentsch-Ullrich, Kathleen, additional, Stegelmann, Frank, additional, Rieger, Christina, additional, Waller, Cornelius F., additional, Franke, Georg-Nikolaus, additional, Junghanss, Christian, additional, Kirchmair, Rudolf, additional, Theurl, Markus, additional, and le Coutre, Philipp, additional

Published
2023
Full Text
View/download PDF

19. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Author

Cortes, Jorge E., Kim, Dong-Wook, Pinilla-Ibarz, Javier, le Coutre, Philipp D., Paquette, Ronald, Chuah, Charles, Nicolini, Franck E., Apperley, Jane F., Khoury, H. Jean, Talpaz, Moshe, DeAngelo, Daniel J., Abruzzese, Elisabetta, Rea, Delphine, Baccarani, Michele, Müller, Martin C., Gambacorti-Passerini, Carlo, Lustgarten, Stephanie, Rivera, Victor M., Haluska, Frank G., Guilhot, François, Deininger, Michael W., Hochhaus, Andreas, Hughes, Timothy P., Shah, Neil P., and Kantarjian, Hagop M.

Published
2018
Full Text
View/download PDF

21. Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia

Author

Cortes, Jorge E., Gambacorti-Passerini, Carlo, Deininger, Michael W., Mauro, Michael J., Chuah, Charles, Kim, Dong-Wook, Milojkovic, Dragana, le Coutre, Philipp, Garcia-Gutierrez, Valentin, Crescenzo, Rocco, Mamolo, Carla, Reisman, Arlene, Hochhaus, Andreas, Brümmendorf, Tim H., and the BFORE Study Investigators

Published
2019
Full Text
View/download PDF

22. Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Author

Kantarjian, Hagop M., Hughes, Timothy P., Larson, Richard A., Kim, Dong-Wook, Issaragrisil, Surapol, le Coutre, Philipp, Etienne, Gabriel, Boquimpani, Carla, Pasquini, Ricardo, Clark, Richard E., Dubruille, Viviane, Flinn, Ian W., Kyrcz-Krzemien, Slawomira, Medras, Ewa, Zanichelli, Maria, Bendit, Israel, Cacciatore, Silvia, Titorenko, Ksenia, Aimone, Paola, Saglio, Giuseppe, and Hochhaus, Andreas

Published
2021
Full Text
View/download PDF

23. Risk of progression in chronic phase‐chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR‐PRO study

Author

Zambrotta, Giovanni Paolo Maria, primary, Nicolini, Franck E., additional, Assouline, Sarit, additional, Busque, Lambert, additional, Pungolino, Ester, additional, Abruzzese, Elisabetta, additional, Miggiano, Maria Cristina, additional, Elena, Chiara, additional, Alvarez‐Larran, Alberto, additional, Triguero, Ana, additional, Iurlo, Alessandra, additional, Bucelli, Cristina, additional, Cerrano, Marco, additional, Capodanno, Isabella, additional, Lunghi, Francesca, additional, le Coutre, Philipp, additional, Galimberti, Sara, additional, Caocci, Giovanni, additional, Maffioli, Margherita, additional, Stagno, Fabio, additional, Saussele, Susanne, additional, Piazza, Rocco, additional, Druker, Brian J., additional, Fava, Carmen, additional, Guglielmana, Veronica, additional, Colombo, Federica, additional, Antolini, Laura, additional, and Gambacorti‐Passerini, Carlo, additional

Published
2023
Full Text
View/download PDF

24. Physical exercise recommendations for patients with polycythemia vera based on preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97)

Author

Felser, Sabine, primary, Rogahn, Julia, additional, Hollenbach, Lina, additional, Gruen, Julia, additional, le Coutre, Philipp, additional, Al‐Ali, Haifa Kathrin, additional, Schulze, Susann, additional, Muegge, Lars‐Olof, additional, Kraze‐Kliebhahn, Veronika, additional, and Junghanss, Christian, additional

Published
2023
Full Text
View/download PDF

25. P674: 2ND-LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) PATIENTS FAILING OR INTOLERANT TO 1ST-LINE 2ND GENERATION TKI THERAPY: INTERIM ANALYSIS OF THE PROSPECTIVE PONS TRIAL

Author

Le Coutre, Philipp, primary, Göthert, Joachim, additional, Saussele, Susanne, additional, Pelzer, Uwe, additional, Bullinger, Lars, additional, Elmaagacli, Ahmet, additional, Jehn, Christian, additional, Stegelmann, Frank, additional, Hochhaus, Andreas, additional, Ernst, Thomas, additional, and Burchert, Andreas, additional

Published
2023
Full Text
View/download PDF

26. P667: RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY

Author

Paolo Maria Zambrotta, Giovanni, primary, Assouline, Sarit, additional, Nicolini, Franck E., additional, Abruzzese, Elisabetta, additional, Pungolino, Ester, additional, Cristina Miggiano, Maria, additional, Elena, Chiara, additional, Alvarez Larran, Alberto, additional, Triguero Moreno, Ana, additional, Iurlo, Alessandra, additional, Bucelli, Cristina, additional, Lunghi, Francesca, additional, Capodanno, Isabella, additional, Maffioli, Margherita, additional, Galimberti, Sara, additional, Caocci, Giovanni, additional, Stagno, Fabio, additional, Saussele, Susanne, additional, Fava, Carmen, additional, Le Coutre, Philipp, additional, Bonifacio, Massimiliano, additional, Guglielmana, Veronica, additional, Colombo, Federica, additional, Antolinni, Laura, additional, and Gambacorti-Passerini, Carlo, additional

Published
2023
Full Text
View/download PDF

27. S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.

Author

Ernst, Thomas, primary, Le Coutre, Philipp, additional, Crysandt, Martina, additional, Brümmendorf, Tim H, additional, Franke, Georg-Nikolaus, additional, Illmer, Thomas, additional, Burchert, Andreas, additional, Lang, Fabian, additional, Saussele, Susanne, additional, Lars Teichmann, Lino, additional, Radsak, Markus, additional, Krause, Stefan, additional, Rinke, Jenny, additional, Fabisch, Christian, additional, Lang, Thomas, additional, Pfirrmann, Markus, additional, and Hochhaus, Andreas, additional

Published
2023
Full Text
View/download PDF

28. S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.

Author

Hochhaus, Andreas, primary, Burchert, Andreas, additional, Saußele, Susanne, additional, Baerlocher, Gabriela M, additional, Mayer, Jiri, additional, Brümmendorf, Tim H, additional, La Rosee, Paul, additional, Heim, Dominik, additional, Krause, Stefan W, additional, Le Coutre, Philipp, additional, Fabisch, Christian, additional, Rinke, Jenny, additional, Lange, Thoralf, additional, Fabarius, Alice, additional, Lorch, Marcel, additional, Hänel, Mathias, additional, Stegelmann, Frank, additional, Franke, Georg-Nikolaus, additional, Radsak, Markus, additional, Kunzmann, Volker, additional, Himsel, Danny, additional, Kohn, Denise, additional, Lang, Thomas, additional, Hehlmann, Rüdiger, additional, Ernst, Thomas, additional, and Pfirrmann, Markus, additional

Published
2023
Full Text
View/download PDF

29. Single-cell analysis based dissection of clonality in myelofibrosis

Author

Mylonas, Elena, Yoshida, Kenichi, Frick, Mareike, Hoyer, Kaja, Christen, Friederike, Kaeda, Jaspal, Obenaus, Matthias, Noerenberg, Daniel, Hennch, Cornelius, Chan, Willy, Ochi, Yotaro, Shiraishi, Yuichi, Shiozawa, Yusuke, Zenz, Thorsten, Oakes, Christopher C., Sawitzki, Birgit, Schwarz, Michaela, Bullinger, Lars, le Coutre, Philipp, Rose-Zerilli, Matthew J. J., Ogawa, Seishi, and Damm, Frederik

Published
2020
Full Text
View/download PDF

30. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial

Author

Cortes, Jorge E, De Souza, Carmino Antonio, Ayala, Manuel, Lopez, Jose Luis, Bullorsky, Eduardo, Shah, Sandip, Huang, Xiaojun, Babu, K Govind, Abdulkadyrov, Kudrat, de Oliveira, José Salvador Rodrigues, Shen, Zhi-Xiang, Sacha, Tomasz, Bendit, Israel, Liang, Zhizhou, Owugah, Tina, Szczudlo, Tomasz, Khanna, Sadhvi, Fellague-Chebra, Rafik, and le Coutre, Philipp D

Published
2016
Full Text
View/download PDF

31. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

Author

Ross, David M., Masszi, Tamas, Gómez Casares, María Teresa, Hellmann, Andrzej, Stentoft, Jesper, Conneally, Eibhlin, Garcia-Gutierrez, Valentin, Gattermann, Norbert, le Coutre, Philipp D., Martino, Bruno, Saussele, Susanne, Giles, Francis J., Radich, Jerald P., Saglio, Giuseppe, Deng, Weiping, Krunic, Nancy, Bédoucha, Véronique, Gopalakrishna, Prashanth, and Hochhaus, Andreas

Published
2018
Full Text
View/download PDF

33. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

Author

Lipton, Jeffrey H, Chuah, Charles, Guerci-Bresler, Agnès, Rosti, Gianantonio, Simpson, David, Assouline, Sarit, Etienne, Gabriel, Nicolini, Franck E, le Coutre, Philipp, Clark, Richard E, Stenke, Leif, Andorsky, David, Oehler, Vivian, Lustgarten, Stephanie, Rivera, Victor M, Clackson, Timothy, Haluska, Frank G, Baccarani, Michele, Cortes, Jorge E, Guilhot, François, Hochhaus, Andreas, Hughes, Timothy, Kantarjian, Hagop M, Shah, Neil P, Talpaz, Moshe, and Deininger, Michael W

Published
2016
Full Text
View/download PDF

34. Nilotinib

Author

Ostendorf, Benjamin N., le Coutre, Philipp, Kim, Theo D., Quintás-Cardama, Alfonso, Schlag, Peter M., Series editor, Senn, Hans-Jörg, Series editor, and Martens, Uwe M., editor

Published
2014
Full Text
View/download PDF

35. Nilotinib

Author

Gresse, Martin, primary, Kim, Theo D., additional, and le Coutre, Philipp, additional

Published
2018
Full Text
View/download PDF

37. Anxieties, age and motivation influence physical activity in patients with myeloproliferative neoplasms - a multicenter survey from the East German study group for hematology and oncology (OSHO #97)

Author

Felser, Sabine, primary, Rogahn, Julia, additional, le Coutre, Philipp, additional, Al-Ali, Haifa Kathrin, additional, Schulze, Susann, additional, Muegge, Lars-Olof, additional, Gruen, Julia, additional, Geissler, Jan, additional, Kraze-Kliebhahn, Veronika, additional, and Junghanss, Christian, additional

Published
2023
Full Text
View/download PDF

40. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis

Author

Giles, Francis J., Rea, Delphine, Rosti, Gianantonio, Cross, Nicholas C. P., Steegmann, Juan Luis, Griskevicius, Laimonas, le Coutre, Philipp, Coriu, Daniel, Petrov, Ljubomir, Ossenkoppele, Gert J., Mahon, Francois-Xavier, Saussele, Susanne, Hellmann, Andrzej, Koskenvesa, Perttu, Brümmendorf, Tim H., Gastl, Gunther, Castagnetti, Fausto, Vincenzi, Beatrice, Haenig, Jens, and Hochhaus, Andreas

Published
2017
Full Text
View/download PDF

41. Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis

Author

Hochhaus, Andreas, Mahon, Franҫois-Xavier, le Coutre, Philipp, Petrov, Ljubomir, Janssen, Jeroen J. W. M., Cross, Nicholas C. P., Rea, Delphine, Castagnetti, Fausto, Hellmann, Andrzej, Rosti, Gianantonio, Gattermann, Norbert, Coronel, Maria Liz Paciello, Gutierrez, Maria Asuncion Echeveste, Garcia-Gutierrez, Valentin, Vincenzi, Beatrice, Dezzani, Luca, and Giles, Francis J.

Published
2017
Full Text
View/download PDF

42. Second-Line Ponatinib in Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients Failing or Intolerant to First-Line Second Generation Tyrosine Kinase Inhibitor (TKI) Treatment: An Interim Analysis of the Prospective PONS Trial

Author

le Coutre, Philipp, primary, Göthert, Joachim R, additional, Saussele, Susanne, additional, Pelzer, Uwe, additional, Bullinger, Lars, additional, Elmaagacli, Ahmet, additional, Jehn, Christian, additional, Stegelmann, Frank, additional, Hochhaus, Andreas, additional, Ernst, Thomas, additional, and Burchert, Andreas, additional

Published
2022
Full Text
View/download PDF

43. ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase

Author

Ernst, Thomas, primary, Schönfeld, Lioba, additional, Rinke, Jenny, additional, Hinze, Anna, additional, Nagel, Saskia N., additional, Schäfer, Vivien, additional, Schenk, Thomas, additional, Fabisch, Christian, additional, Brümmendorf, Tim H., additional, Burchert, Andreas, additional, le Coutre, Philipp, additional, Krause, Stefan W., additional, Saussele, Susanne, additional, Safizadeh, Fatemeh, additional, Pfirrmann, Markus, additional, and Hochhaus, Andreas, additional

Published
2022
Full Text
View/download PDF

44. Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)

Author

Kohlbrenner, Katharina, primary, Galuschek, Norbert, additional, Fabarius, Alice, additional, Reiser, Marcel, additional, Fenchel, Klaus, additional, Eßeling, Eva, additional, Göhler, Thomas, additional, Geer, Thomas, additional, Depenbusch, Reinhard, additional, Azeh, Ivo Talah, additional, Engel, Erik, additional, Hansen, Richard, additional, Lindemann, Hans-Walter, additional, Anhuf, Jürgen, additional, Jehner, Paul, additional, Abu-Samra, Maisun, additional, Ritter, Markus, additional, Gattermann, Norbert, additional, Pelz, Henning, additional, Fuxius, Stefan, additional, Oswald, Burkhard, additional, Baerlocher, Gabriela M, additional, Brummendorf, Tim H.H., additional, Heim, Dominik, additional, le Coutre, Philipp, additional, Burchert, Andreas, additional, Niederwieser, Dietger, additional, Tesch, Hans, additional, Hofmann, Wolf-Karsten, additional, Hochhaus, Andreas, additional, Hehlmann, Rüdiger, additional, and Saussele, Susanne, additional

Published
2022
Full Text
View/download PDF

45. Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study

Author

Zambrotta, Giovanni, primary, Assouline, Sarit, additional, Nicolini, Franck E., additional, Abruzzese, Elisabetta, additional, Miggiano, Maria Cristina, additional, Elena, Chiara, additional, Alvarez-Larran, Alberto, additional, Triguero, Ana, additional, Iurlo, Alessandra, additional, Bucelli, Cristina, additional, Lunghi, Francesca, additional, Capodanno, Isabella, additional, Maffioli, Margherita, additional, Galimberti, Sara, additional, Caocci, Giovanni, additional, Stagno, Fabio, additional, Saussele, Susanne, additional, Fava, Carmen, additional, le Coutre, Philipp, additional, Bonifacio, Massimiliano, additional, Guglielmana, Veronica, additional, Colombo, Federica, additional, Antolini, Laura, additional, and Gambacorti-Passerini, Carlo, additional

Published
2022
Full Text
View/download PDF

46. Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Author

Burchert, Andreas, primary, Saussele, Susanne, additional, Michel, Christian, additional, Metzelder, Stephan K, additional, Hochhaus, Andreas, additional, Gattermann, Norbert, additional, Crysandt, Martina, additional, Schafhausen, Philippe, additional, Bormann, Matthias, additional, Radsak, Markus P., additional, Guerci-Bresler, Agnès, additional, Illmer, Thomas, additional, Goebeler, Maria E, additional, Herhaus, Peter, additional, Teichmann, Lino L., additional, Franke, Georg-Nikolaus, additional, Lang, Fabian, additional, Krause, Stefan W., additional, Möhle, Robert, additional, Klausmann, Martine, additional, Stegelmann, Frank, additional, Lutz, Christoph, additional, Etienne, Gabriel, additional, Stoltefuß, Andrea, additional, Göthert, Joachim R, additional, Ernst, Thomas, additional, Neubauer, Andreas, additional, Hehlmann, Rüdiger, additional, Aminossadati, Behnaz, additional, Wittenberg, Michael, additional, Pfirrmann, Markus, additional, Schade-Brittinger, Carmen, additional, le Coutre, Philipp, additional, and Nicolini, Franck E., additional

Published
2022
Full Text
View/download PDF

47. Therapy-Related AML: Clinical/Biological Features and Long-Term Outcome in a Cohort of 1133 Adult AML Patients

Author

Gross, Sophia, primary, Ihlow, Jana, additional, Busack, Leonie, additional, Adamiak, Kacper, additional, Schrezenmeier, Jens F., additional, Jesse, Julia, additional, Schwarz, Michaela, additional, Floercken, Anne, additional, Rieger, Kathrin, additional, Krönke, Jan, additional, le Coutre, Philipp, additional, Boldt, Vivien, additional, von Bruenneck, Ann-Christin, additional, Horst, David, additional, Burmeister, Thomas, additional, Blau, Igor Wolfgang, additional, Keller, Ulrich, additional, Bullinger, Lars, additional, and Westermann, Joerg, additional

Published
2022
Full Text
View/download PDF

49. Nilotinib

Author

Quintás-Cardama, Alfonso, Kim, Theo Daniel, Cataldo, Vince, le Coutre, Philipp, and Martens, Uwe M., editor

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results